Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:3/7/2011

CAMBRIDGE, Mass., March 7, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that management will present a corporate overview at the Roth 23rd Annual Growth Stock Conference on Monday, March 14, 2011 at 12:00 p.m. PT at the Ritz Carlton Laguna Niguel in Dana Point, California and at the Barclays Capital 2011 Global Healthcare Conference on Thursday, March 17, 2011 at 11:15 a.m. ET at the Loews Miami Hotel, Florida.

The live and archived webcasts of the company presentations can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com.  Please log in approximately 5-10 minutes before each event to ensure a timely connection.  The archived replays will be available on the Idenix website for two weeks following the conferences.  

About IdenixIdenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus. For further information about Idenix, please refer to http://www.idenix.com.Idenix Pharmaceuticals Contact:Kelly Barry (617) 995-9033 (media)Eric Hoffman (617) 224-4485 (investors)
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
2. Idenix to Host Conference Call Discussing Fourth Quarter and Year End 2010 Financial Results
3. Idenix Pharmaceuticals Reports Third Quarter and Nine Month 2010 Financial Results
4. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
7. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
8. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
9. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
10. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
11. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/26/2016)... , April 26, 2016 Diplomat Pharmacy, ... of Jennifer Hagerman , Pharm D., to Vice ... growing role at Diplomat, Hagerman will continue to lead ... company that delivers custom education and training to Diplomat ... specialty pharmacy industry. Diplomat University also houses the quality ...
(Date:4/26/2016)... , April 26, 2016 Research ... and Credit Risk Analysis of the Biological Medicine Industry ... This comprehensive report analyzes the financial assessment and credit ... China . The report provides readers with an ... all market participants should be aware of. It considers ...
Breaking Medicine Technology:
(Date:4/28/2016)... ... 2016 , ... One way to ignore solid evidence is to dismiss research ... toss the baby out with the bathwater when we ignore all studies because some ... and otherwise making better use of education policy research. , “When readers heed basic ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... USA Medical Card reminds us that May ... (CDC), a stroke is the fourth leading cause of death in the United States; someone ... almost a quarter of them in individuals under 65 years old. A stroke is ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... today announced a new Residency Education & Collaboration Platform for hospitals and ... resources, and a host of collaboration tools designed to improve patient outcomes ...
(Date:4/28/2016)... ... 2016 , ... A first-time look at workers’ compensation claims in Kentucky found ... Compensation Research Institute (WCRI) announced, and that costs per claim were stable between ... Edition , found that indemnity costs per claim and benefit delivery expenses per claim ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... has partnered with Community Oncology Pharmacy Association (COPA) to develop a comprehensive Specialty ... of oncology by introducing an accreditation distinction. ACHC provides a wide range of ...
Breaking Medicine News(10 mins):